Introduction
CRKL is a 39 kDa adapter protein containing one SH2 and two SH3 domains. The CRKL gene was originally identi®ed by ten Hoeve et al. (1993) and found to be in close proximity to the BCR gene on human chromosome 22q11. The CRKL protein has an overall amino acid homology of 60% to CRK II, one of two proteins generated through alternative splicing of the human crk proto-oncogene. CRK I lacks the Cterminal SH3 domain of CRK II, but overexpression of either CRK I or CRKL, but not CRK II, leads to transformation of ®broblasts (Matsuda et al., 1992; Senechal et al., 1996) . CRK was identi®ed by its homology to v-crk, the oncogene in the avian retrovirus CT10, which diers from CRK by deletion of the C-terminal SH3 domain and the major tyrosine phosphorylation site at tyr 221 (Mayer et al., 1988) . CRKL and/or CRK have been shown to be involved in a number of signaling pathways, including pathways activated by T cell stimulation (Sawasdikosol et al., 1995) , EGF receptor activation (Birge et al., 1992) , and hematopoietic cytokine receptor activation (Barber et al., 1997; Sattler et al., 1997a) . Further, we have previously shown that CRKL is tyrosine phosphorylated after integrin cross-linking (Sattler et al., 1997b) . However, the exact roles of either CRK and CRKL in any of these normal signaling pathways are unknown.
A number of cellular proteins have been shown to bind to the CRKL and CRK SH3 domains, including c-ABL, C3G, EPS15, DOCK180, and SOS (Feller et al., 1994; Ren et al., 1994; ten Hoeve et al., 1994b; Tanaka et al., 1994; Uemura et al., 1997; Schumacher et al., 1995; Hasegawa et al., 1996; Feller et al., 1995) . Several proteins have also been identi®ed which interact with the CRKL or CRK SH2 domains, including c-CBL, CAS, HEF1, and paxillin (Sawasdikosol et al., 1995; de Jong et al., 1995; Sattler et al., 1996 Sattler et al., , 1997b Sakai et al., 1994; Salgia et al., 1996a,b; Birge et al., 1993) . In vitro, the proteins which can interact with CRKL and CRK appear to be similar, although a few dierences have been noted. Immunoprecipitation studies suggest that CRKL and CRK bind constitutively to proteins such as C3G which bind to their SH3 domains, while interaction with the SH2-binding proteins requires tyrosine phosphorylation of the target protein, typically involving a pY-X-X-P motif Salgia et al., 1996b; Andoniou et al., 1996) .
CRKL is a prominent tyrosine phosphoprotein in cells transformed by the BCR/ABL oncogene, and we and others have previously shown that CRKL binds to BCR/ABL through its N-terminal SH3 domain (Oda et al., 1994; Nichols et al., 1994; ten Hoeve et al., 1994a) . In these transformed cells, CRKL links BCR/ABL to p120c-CBL, which is also heavily phosphorylated on tyrosine residues. PI3K joins this complex through binding to CBL, thus forming a multimeric complex with BCR/ABL (Sattler et al., 1996) . The site of tyrosine phosphorylation of CRKL in BCR/ABLtranformed cells has been identi®ed as Y207 (de Jong et al., 1997) . The consequences of CRKL phosphorylation are unknown, although phosphorylation of the homologous tyrosine residue in CRK has been reported to form an intramolecular binding site for the CRK SH2 domain (Feller et al., 1994; Rosen et al., 1995) .
In the present study, we sought to investigate the biological consequences of CRKL signaling by overexpressing CRKL or CRKL mutants in growth factordependent hematopoietic cell lines. The results indicate that CRKL may be involved in pathways which regulate adhesion to extracellular matrix proteins such as ®bronectin. Interestingly, recent studies suggest that v-crk may have have a similar eect on adhesion (Altun-Gultekin et al., 1998) .
Results

Biological eects of overexpression of wild-type and deletion mutants of CRKL in hematopoietic cell lines
The IL-3 dependent hematopoietic cell line Ba/F3 was transfected with vectors expressing either wild-type CRKL, CRKLDSH2 or CRKLDSH3(N) cDNAs. Similarly, IL-3 dependent 32Dcl3 cells were transfected with either wild-type CRKL or CRKLDSH3(N) cDNAs (Figure 1a ). After selection in G418 and a b c Figure 1 Expression of wild-type and mutant CRKL proteins in Ba/F3 and 32Dcl3 cells. (a) Diagrams of structure of wild-type and mutant CRKL proteins. All constructs were tagged at the C-terminus with an HA tag. (b) Western blotting with anti-CRKL mAb (#5 ± 6) of whole cell lysates (1610 6 cells) from two representative clones of each line and mock-transfected cells. CRKL with HA-tag migrated at &40 kDa and CRKL-DSH2 or CRKL-DSH3(N) with HA-tag migrated at &34 kDa. Endogenous CRKL migrated at 39 kDa. (c) Lysates from 1610 7 cells of a representative clone of each line and mock-transfected cells were immunoprecipitated with anti-CRKL mAb. Immunoprecipitates and whole cell lysates from 1610 6 cells were subjected to Western blotting with antibodies against several CRKL-SH3 binding proteins (C3G, ABL, and p85P13K) and CRKL screening by Western blotting, 3 ± 5 independent subclones which overexpressed each transgene were obtained. The expression of CRKL proteins in two representative clones of each line is shown in Figure  1b . Each transgene was typically expressed at a 5 ± 10-fold increase over that of endogenous CRKL. Another (d) Adhesion of Ba/F-mock and two representative clones of BaF-CRKL was determined in a short term adhesion assay in the presence or absence of an anti-b1 integrin antibody (Ha2/5) which can inhibit b1 integrin function. Ha2/5 or hamster lgM (as a control) was added to cell suspensions for 30 min at 378C prior to the adhesion assay monoclonal antibody, anti-CRKL #2-2, which recognizes an epitope located within the N-terminal SH3 domain (Uemura et al., 1997) , detected equivalent overexpression of the wild-type and DSH2 CRKL mutant proteins, but but did not detect the DSH3(N) mutant CRKL protein, con®rming expression of the appropriate transgene in the DSH3 mutants (data not shown). The two clones shown in Figure 1 of each line were those evaluated in all subsequent experiments. The interaction of overexpressed CRKL proteins with cellular proteins was examined by looking for coprecipitation of speci®c cellular proteins in anti-CRKL immune complexes. Coprecipitation of CRKL with three proteins known to bind to CRKL-SH3 domains, C3G, ABL and the p85 subunit of PI3K, was a c b Figure 3 Overexpression of CRKL does not induce expression of total b1 integrins nor the 9EG7 epitope on b1 integrins. (a, b) Total b1 integrin surface expression of two representative clones of Ba/F3 (a) or 32Dcl3 (b) was measured using an anti-b1 integrin antibody, HMb1-1 using FACS. The verical axis shows mean¯uorescence intensity. (c) Ba/F-mock (*), Ba/F-CRKL (clones 1 and 2; &) and Ba/F-CRKLDSH3N (clones 1 and 2;~) cells were analysed for expression of the 9EG7 epitope after exposure to a peptide ligand (GRGDSP; 0-1000 mM for 30 min at 378C). Binding of the 9EG7 monoclonal antibody was dectected by FACS. Vertical axis; mean¯uorescence intensity, horizontal axis; concentration of GRGDSP peptide added. The diagonal bars within the graph indicate discontinuity of the log scale to show the zero value. The data shown is a representative experiment of a total of two. To con®rm that the 9EG7 antibody recognizes a conformational change of activated' b1 integrin, expression of the HMb1-1 epitope and the 9EG7 epitope was compared before and after the treatment with manganese (MnCl 2 , 3 mM, 30 min) which is known to strongly induce a conformational change of b1 integrin. The 9EG7 epitope increased after manganese treatment [mean¯uorescence intensity increased from 0.77 ± 1.53 (log scale, arbitrary units)], while the HMb1-1 epitope did not change (mean¯uorescence intensity: 3.01 vs. 3.11) determined. Coprecipitation of CRKL with C3G, ABL and p85PI3K was increased in Ba/F3 overexpressing wild-type CRKL and the CRKLDSH2 as compared to mock transfected cells, but not in cells overexpressing a DSH3(N) mutant of CRKL ( Figure 1c ). Similar results were seen in 32Dcl3 cells. The coprecipitation of small amounts of C3G and p85Pl3K with CRKL in cells overexpressing CRKLDSH3 was attributed to the presence of endogenous CRKL in the immune complex. We also looked for CRKL-SH2 binding proteins in Ba/F3 cells, but found only trace amounts of tyrosine phosphoproteins in anti-CRKL immunoprecipitations in these cells, consistent with our previous ®ndings in IL-3-stimulated Ba/F3 cells using CRKL fusion proteins as probes in far Western blots (Uemura et al., 1997) . However, Chin et al. (1997) reported that several proteins including CBL are coprecipitated with CRKL after IL-3 stimulation in another cell line, 32D.
All lines overexpressing wild-type CRKL or CRKL deletion mutants were analysed to determine if these proteins aected IL-3 dependence, growth rates, or viability. All lines grew at similar rates in the presence of IL-3, and died within two days in the absence of IL-3 (data not shown). The Ba/F3 cell lines were also tested for radiation sensitivity by serially measuring viability after 10 ± 40 Gy ionizing radiation. Again, overexpression of CRKL or the CRKL deletion mutants tested here had no demonstrable eects on radiation-induced apoptosis (data not shown).
Eects of CRKL on cell adhesion to ®bronectin
CRKL is known to bind to several focal adhesion proteins, including paxillin, thought to be involved in regulating integrin signaling or function. Therefore, we next examined cell adhesion of these lines to ®bronectin-coated surfaces using a short-term (30 min) adhesion assay. Cell lines were in log phase of growth in IL-3 containing medium when tested. Adhesion of Ba/F-CRKL cells was signi®cantly increased as compared to Ba/F-mock cells. In contrast, overexpression of either CRKLDSH3(N) or CRKLDSH2 mutants in Ba/F3 cells did not lead to increased adhesion in multiple assays, and cells overexpressing CRKLDSH3(N) had somewhat reduced adhesion compared to mock transfected cells ( Figure 2a ). Similar results were obtained on each of two independent clones of each transfectant, as shown in Figure 2a , where each experiment was repeated six times. In studies not shown, similar results were also obtained with these cell lines either with or without prior IL-3 deprivation.
Adhesion assays were also performed on surfaces coated with other extracellular matrix proteins (each at 5 mg/cm 2 ), including collagen I, collagen IV, laminin, and vitronectin. The Ba/F3 derived lines did not adhere to collagen I, collagen IV, or laminin at all. However, short-term adhesion of Ba/F3 derived lines to vitronectin was similarly enhanced by overexpression of wild-type CRKL, but not by overexpression of the DSH3(N) mutant of CRKL (data not shown). The eects of CRKL overexpression on cell adhesion to ®bronectin were also examined using 32Dcl3 cells (Figure 2b ). Wild-type CRKL enhanced adhesion to ®bronectin, while overexpression of CRKLDSH3(N) had no eect or was modestly inhibitory.
The eects of CRKL overexpression were also evaluated in Ba/F3 cells after transient transfection of a construct in which CRKL and green¯uorescent protein (GFP) were expressed as separate proteins through a single transcript so that transfected cells could be easily detected using¯uorescence. In three separate experiments, after enriching transfected cells by¯uorescence-activated cell sorting (FACS) to 495% purity, Ba/F3 cells which expressed wild-type CRKL and GFP had increased short-term adhesion to ®bronectin when compared to equally brightlȳ uorescent Ba/F3 cells transfected with the same vector expressing CRKLDSH3(N) or GFP alone (Figure 2c) .
Since adhesion to extracellular matrix proteins such as ®bronectin is mediated by integrins, we tested the eects of adding an anti-b1 integrin antibody to the adhesion assays. As expected, this antibody blocked binding of Ba/F-mock as well as Ba/F-CRKL clones by 490% (Figure 2d ). The possibility that CRKL overexpression augmented b1-integrin surface expression was therefore considered, but FACS analysis with an anti-b1-integrin monoclonal antibody showed no detectable eect (Figure 3a,b) . Finally, we considered the possibility that CRKL overexpression induced b integrins to enter an activated state. We therefore looked for spontaneous induction of the activation epitope identi®ed by the 9EG7 monoclonal antibody. However, as shown in Figure 3c , overexpression of CRKL did not aect either spontaneous or ligandinduced expression of this epitope, indicating that the eects of CRKL on adhesion are not likely mediated by directly increasing integrin anity for ligand, but modifying post-integrin receptor events. Figure 4 Overexpression of CRKL induces abnormal cell motility on ®bronectin. Ba/F-CRKL cells were plated onto ®bronectin-coated plate, and observed using time-lapse video microscopy. The pictures shown were captured from the video showing the same ®eld at 5 min intervals. The cell indicated by dark arrows was moving to the right side. The images show the formation of a long cellular extension forming from the trailing edge of the cell body. The smaller arrow shows a trailing cellular extension that is continuing to elongate as the cell migrates further to the right CRKL overexpression alters cell morphology
In the experiments described above, we noted that occasional cells overexpressing wild-type CRKL, but not CRKL deletion mutants or mock transfected cells, had a speci®c change in morphology characterized by the presence of long, ®ne, cytoplasmic protrusions. This morphological change was present in less than 1% of CRKL-transfected cells at any single point in time. Using time-lapse video microscopy on ®bronectin-coated surfaces, these structures appeared to form at the trailing edge of the cell (Figure 4) . These protrusions contained F-actin when stained by rhodamine-phalloidin (data not shown). The number of CRKL-overexpressing cells with these long trailing protrusions was markedly reduced when cells were cultured on plastic, rather than ®bronectin, suggesting that integrin crosslinking in some way contributes to this change. In an experiment in which cells were irradiated to examine the eects of CRKL overexpression on viability after ionizing radiation, we noted that this morphological change was strikingly enhanced. In more detailed studies (Figure 5 ), gamma radiation increased the number of cells with this altered morphology, modestly for untransfected, mock-transfected, or CRKL deletion mutant overexpressing cells, and strikingly for all sublines of Ba/F3 overexpressing wild-type CRKL (Figure 5a ). 32Dcl3 derived sublines were also evaluated for CRKL-related changes in morphology, and similar results were obtained (Figure 5b ). To ensure that this phenomenon was not nonspeci®cally selected for during the derivation of these stable cell lines, the eects of transient expression of GFP ± CRKL or GFP were evaluated in Ba/F3 cells (% GFP positive cells) of Ba/F3 cells (25 ± 65%) was higher than 32D cells (55%), but in both cases, cells with long cytoplasmic protrusions were observed more often among GFP ± CRKL transfected Ba/F3 and 32Dcl3 cells as compared with GFP-alone transfected Ba/F3 and 32Dcl3 cells, respectively (Figure 5c ). To exclude the possibility that the GFP ± CRKL fusion protein does not re¯ect the function of CRKL alone, these studies were repeated with a new vector, pE-CRKL-IRES-EGFP, in which CRKL and GFP are separately expressed, and again similar ®ndings were obtained. These results suggest that overexpression of CRKL, either transiently or stably, alters cell morphology, and that under certain conditions of cell stress, such as gamma-irradiation, this morphological change is further enhanced. It is possible that the synergy between radiation and CRKL overexpression is due to the enhancement of cell-cell and cell-matrix adhesion known to be caused by gamma radiation (Onoda et al., 1992; Jacobson et al., 1996) . We found that radiation of either Ba/F3 or 32Dcl3 cells (10 Gy) increases adhesion to ®bronectin within 6 h without increase in the surface b1 integrin expression (data not shown).
Discussion
In this study, we have examined the biological eects of overexpressing full length or SH2/SH3 deletion mutants of CRKL in two IL-3-dependent hematopoietic cell lines, Ba/F3 and 32Dcl3. In both lines, IL-3 is required for viability, induces proliferation, and also transiently enhances adhesion to ®bronectin (Bazzoni et al., 1996) . A series of Ba/F3 and 32Dcl3 cell lines stably expressing wild-type CRKL, CRKLDSH2 or CRKLDSH3(N) were generated, and in several independently derived sublines, overexpression of these proteins had no demonstrable eect on viability or proliferation in the presence or absence of IL-3. However, adhesion to ®bronectin was enhanced by wild-type CRKL, but not by CRKL mutants lacking either the N-terminal SH3 domain or the SH2 domain. The eects of CRKL on adhesion to ®bronectin were con®rmed by observing similar eects in both Ba/F3 and 32Dcl3 cells after transient expression of CRKL and CRKL deletion mutants. These results suggest that CRKL is involved in a signaling pathway that regulates cellular adhesion through integrins, and further suggest that CRKL may not be a critical component of pathways leading to proliferation or control of cell viability in these cells. Recently, similar eects of CRKL overexpression on cell adhesion to ®bronectin were reported using another hematopoietic cell line, FL5.12 (Senechal et al., 1998) .
The mechanisms whereby CRKL might aect cell adhesion do not appear to involve altering integrin anity. CRKL overexpression does not increase surface expression of b1 integrins and does not lead to increased expression of the activation epitope identi®ed by the 9EG7 monoclonal antibody. Thus, CRKL could aect diusion of integrins to sites of contact, strengthen the connection between an integrin molecule and the cytoskeleton, or alter events which lead to release of integrins from ligand. CRKL is primarily a cytoplasmic protein, although we have previously shown that CRKL can interact through its SH2 domain with several proteins located in part or in whole in the cytoskeleton, including the focal adhesion protein paxillin (Salgia et al., 1995b) , and two related proteins known to be involved in integrin signaling, p130 CAS and HEF1 (Salgia et al., 1996a; Sattler et al., 1997b) . Paxillin is a 68 kDa phosphoprotein located exclusively in focal adhesions which is phosphorylated on serine and tyrosine residues in response to integrin cross-linking in many cell types (Bellis et al., 1997) . Paxillin also interacts directly with at least two other focal adhesion proteins known to be involved in integrin signaling, focal adhesion kinase (FAK) and vinculin (Salgia et al., 1995a) . p130 CAS was initially identi®ed as a prominent tyrosine phosphorylated substrate of the oncoproteins v-src and v-crk (Kanner et al., 1991; Birge et al., 1992) . It has also been shown that p130
CAS is tyrosine phosphorylated in response to adhesion and crosslinking of b1 integrins (Nojima et al., 1995; Manie et al., 1997) . This molecule has been shown to associate with the focal adhesion proteins p125 FAK and tensin in vivo and in vitro (Lo et al., 1994; Polte and Hanks, 1995) . p130 CAS contains an Nterminal SH3 domain which has been shown to bind to the proline rich portion in the C-terminus of p125 FAK . In the middle of the molecule is thè substrate domain' with nine tyr-asp-X-pro motifs optimum for binding the c-CRK-SH2 domain (Sakai et al., 1994) . Mayer and colleagues have shown that the c-Abl-SH2 domain binds to the substrate domain of p130 CAS in vitro (Mayer et al., 1995) . Lo et al. (1994) have shown that the SH2-domain of tensin is also capable of binding p130 CAS in v-src transformed cells. Interestingly, CRK and p130 CAS have recently been linked to the control of migration in an epithelial cell line (Klemke et al., 1998) , suggesting that both CRK and CRKL may contribute to the regulation of several cytoskeletal functions. Overall, while the function of CRKL remains unknown, it is clear that CRKL physically associates with a number of cytoskeletal proteins which are believed to play some role in regulating adhesion. The results presented here further suggest that the amount of CRKL present in a cell can dramatically aect a pathway which enhances adhesion to ®bronectin, possibly by aecting integrin function.
In addition to proteins such as paxillin, CAS, and Hef1 which interact with CRKL through its SH2 domain, there are a number of proteins known to bind to CRKL through its N-terminal SH3 domain, including C3G, c-ABL, and p85P13K. The interaction of CRKL with c-ABL may be of particular interest in integrin signaling. Lewis et al. (1996) have recently shown that cell adhesion regulates the kinase activity and subcellular localization of c-ABL. Binding of ®broblasts to ®bronectin resulted in a transient recruitment of a subset of c-ABL to focal contacts coincident with the export of c-ABL from the nucleus to the cytoplasm. CRKL is known to bind to c-ABL through its SH3 domain. Interestingly, we found that overexpression of a mutant CRKL with a deletion of the N terminal SH3 domain inhibited adhesion to a moderate degree, at least in Ba/F3 cells. These results suggest that the interaction of CRKL with an SH3-binding protein, such as c-ABL, could be important in regulating adhesion to ®bronectin. These results are of interest because of the prominent eects of BCR/ABL on adhesion of cells to ®bronectin and other extracellular matrix proteins, and the apparent involvment of CRKL in BCR/ABL signaling.
C3G is also of potential interest in explaining the activities of CRKL overexpression. Ichiba and colleagues have previously demonstrated that expression of either CRKL or CRK in Cos1 cells signi®cantly increased the guanine-nucleotide exchange activity of C3G for its target, Rap1 (Ichiba et al., 1997) . Both the SH2 and SH3 domains of CRK were required for this activity, but CRK did not stimulate C3G activity in vitro, suggesting that this activation does not involve a simple allostearic mechanism. Interestingly, the requirement for the SH2 domain could be compensated for by the addition of a farnesylation signal to CRK, suggesting that translocation of C3G to the membrane was an important part of the mechanism. We do not have any data which suggest that this particular pathway is important for adhesion signaling, but it would be of interest to determine if overexpressing CRKL activates C3G, and thereby Rap1. Rap1, also known as smg p21 or Krev-1, was originally identi®ed by its ability to reverse the morphologic transformation of of v-Ki-ras-transformed ®broblasts (Kitayama et al., 1989) . Rap1 is likely to antagonize p21 ras function by competing for binding to ras eector molecules, such as Raf-1. Interestingly, Rap1 has been implicated in regulating cytoskeletal function and cell morphology in Dictyostelium (Rebstein et al., 1997) . Also, BUD1, a homolog of rap1 in Saccharomyces cerevisiae, forms a complex with BUD5 (a homolog of GDI), BEMI, CDC24, and CDC42 and has been linked to cytoskeletal structure in yeast (White et al., 1993) , and speci®cally with the determination of cell polarity (Park et al., 1997) . Thus, activation of Rap1 could be expected to alter cytoskeletal structure in mammalian cells, and it will be worthwhile to determine if CRKL overexpression exerts its eects on adhesion through C3G activation and subsequent activation of Rap1.
The eects of CRKL overexpression on cell morphology were of interest. A small fraction of cells overexpressing CRKL, but not CRKL deletion mutants, displayed long cytoplasmic protrusions that contained actin. This morphological change occurs within 30 min on ®bronectin, and is consistent, although only a small fraction of cells display this morphological change at any single point in time. Time lapse video microscopy suggested that these structures formed from the trailing edge of motile cells, and appeared to be caused by a failure to release from the extracellular matrix at an appropriate time. The observations made in stable expressing cell lines were con®rmed after transient transfection of CRKL, CRKLDSH2 or CRKLDSH3(N) in both Ba/F3 and 32D cells. This complex change in cytoskeletal morphology was dramatically enhanced by at least one stress, radiation, in both Ba/F3 and 32D cells. Recently, it has been reported that a related protein, vCrk, induced stress ®bers, focal adhesion, lamellipodia and¯attened phenotype in PC12 cells (Altun-Gultekin et al., 1998) . These results suggest that overexpression of CRKL may aect cytoskeletal morphology as well as cell adhesion on a ®bronectin coated surface.
Overall, the results presented suggest that although CRKL may be involved in a number of signaling pathways, in hematopoietic cells, a major biological function is likely related to regulation of adhesion, possibly involving integrin function. The identi®cation of possible dominant negative mutant of CRKL (DSH3(N)) should provide a valuable tool to dissect the critical pathway involved here in more detail. Finally, the results have implications for the understanding of the myeloproliferative disorder CML, where we and others have previously shown that CRKL is a prominent substrate of BCR/ABL tyrosine kinase. Since these cells have constitutive increases in adhesion to ®bronectin, it will be of great interest to determine if that eect is mediated by CRKL.
Materials and methods
Plasmids
A human CRKL cDNA was obtained from Dr John Groen (Children's Hospital, Los Angeles, CA, USA). A hemagglutinin tag sequence was added before the stop codon by PCR, and the resulting cDNA was cloned into the mammalian expression vector pEBBneo. An SH2-domain deletion mutant (CRKLDSH2) and an N-terminal SH3-domain deletion mutant (CRKLDSH3(N)), corresponding to in-frame deletions of amino acids 14 ± 64 and amino acids 131 ± 179, respectively, were made by PCR. A CRKL-green¯uorescent protein (GFP) fusion construct was constructed by inserting the open reading frame of CRKL into expression vector pEGFP-C (Clontech, Palo Alto, CA, USA) to create pEGFP-C-CRKL. Also, the CRKL and CRKL-DSH3(N) cDNA's were cloned into pE-IRES-EGFP plasmid, which was generated from pIRES-EGFP (Clontech) replacing the promoter with EF1a (Mizushima and Nagata, 1990) , to create pE-CRKL-IRES-EGFP or pE-CRKLDSH3(N)-IRES-EGFP.
Cell lines and cell culture
The murine hematopoietic cell lines, Ba/F3 and 32Dcl3, were cultured in RPMI1640 containing 10% fetal calf serum (FCS) and 15% WEHI-3B conditioned medium (WEHI-CM) as a source of IL-3. Ba/F3 cells which stably overexpress wild-type CRKL, CRKLDSH2 and CRKLDSH3(N) (Ba/F-CRKL, Ba/ F-CRKLDSH2, and Ba/F-CRKLDSH3(N)) were generated by transfection of pEBBneo-CRKL, pEBBneo-CRKLDSH2, or pEBBneo-CRKLDSH3(N), respectively, by electroporation. Transfected cells were divided in 24-well culture plates and selected with G418 (1 mg/ml), and 3 ± 5 independent subclones of each were obtained after con®rming the expression of the transgene by Western blotting. Also, a polyclonal control cell line (Ba/F-mock) was generated by transfecting Ba/F3 cells with the pEBBneo vector and selecting in G418 as above. 32Dcl3 cells which stably overexpress wild-type CRKL and CRKL-DSH3(N) (32D-CRKL and 32D-CRKLDSH3(N)) as well as 32D-mock were generated by the same procedure. All these cells were maintained in RPMI 1640 containing 10% FCS and 15% WEHI-CM.
Transient expression
Cells were transfected with pEGFP-C or pEGFP-C-CRKL, as well as pE-IRES-EGFP, pE-CRKL-IRES-EGFP or pE-CRKLDSH3(N)-IRES-EGFP by electroporation using standard conditions (Matulonis et al., 1993) . Twenty-four hours after transfection, cells were treated with 10 Gy ionizing radiation using a Gammacell 1000 (Atomic Energy of Canada) and plated in 35-mm plates coated with fibronectin (5 mg/cm 2 ). Eight hours after plating, cells were observed under phase-contrast and¯uorescence microscopy using an Olympus inverted system microscope equipped with standard FITC ®lters. To enrich GFP expressing cells, cells were sorted by an EPICS Elite-EPS cytometer (Coulter Corp., Hialeah, FL, USA) using a FITC ®lter. FACS-puri®ed cells were tested for adhesion to ®bronectin and analysed for morphological changes as described above.
Immunoblotting and immunoprecipitation
Cells were lysed in buer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 10% glycerol, 1% NP-40 (w/v), 10 mM EDTA, 100 mM NaF, 1 mM phenylmethylsulfonyl¯uoride, 20 mg/ml aprotinin, 1 mM sodium orthovanadate, and 40 mg/ml leupeptin at 10 8 cells/ml. For immunoprecipitation, cell lysates were incubated with anti-CRKL antibody (monoclonal antibody #5 ± 6) (Uemura et al., 1997) and protein A sepharose for 3 h at 48C. Protein samples were separated under reducing conditions by SDS-polyacrylamide gel electrophoresis and transferred to Immobilon PVDF membranes by electroblotting. The membranes were blocked with 5% non-fat dry milk in TBS (10 mM Tris, pH 8.0, 150 mM NaCl) and probed with primary antibodies overnight at 48C. The primary antibodies used were anti-CRKL (5 ± 6), anti-ABL (Ab-3; Oncogene Science, Manhasset, NY, USA), anti-C3G polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti-p85PI3K polyclonal antibody (Upstate Biotechnology, Lake Placid, NY, USA). After washing, membranes were further probed with HRPcoupled secondary antibodies for 1 h, washed and subjected to the ECL chemiluminescence system (Amersham).
Adhesion assays
Cell adhesion to ®bronectin was performed as previously described (Bazzoni et al., 1996) . Brie¯y, 96-well plates were coated with ®bronectin (5 mg/cm 2 : GIBCO ± BRL, Gaithersburg, MD, USA), and blocked with 0.1% heat-inactivated BSA. Cells were labeled with the¯uorescent dye BCECF-AM (Molecular Probes, Eugene, OR, USA), and were added to each well (5610 4 cells/100 ml of RPMI 1640 containing 0.1% heat-inactivated BSA/well). Then, plates were incubated for 30 min at 378C followed by washing with warm RPMI to remove unbound cells. Plates were subjected to a¯uorescence analyzer Cyto¯uor 2300 (Millipore, Bedford, MA, USA) before and after washing. After adjustment by input value (before washing) and subtraction of background cell binding to BSA-coated wells, estimates of cells bound/mm 2 were calculated. In some experiments, an anti-b1 integrin antibody, Ha2/5 (Pharmingen, San Diego, CA, USA) was added to adhesion assays to determine the role of b1 integrins in the adhesion to ®bronectin.
Flow cytometry
Total b1 integrin surface expression was measured using an anti-b1 integrin antibody, HMb1-1 (Pharmingen) and uorescence activated¯ow cytometry (FACS, Coulter Elite, Coulter Corporation, Miami, FL, USA). Expression of the conformational epitope detected by monoclonal antibody 9EG7 on b1 integrin has previously been shown to be associated with ligand binding or activation (Lenter et al., 1993) . The 9EG7 epitope was measured as described previously (Bazzoni et al., 1996) . Brie¯y, starved cells were washed twice with Tris-buered saline, and incubated for 30 min at 378C with or without a peptide ligand for b1 integrins (GRGDSP; GIBCO ± BRL). Monoclonal antibody 9EG7 (Pharmingen) was then added and¯uorescence detected by FACS.
Phase contrast and time-lapse video microscopy
Cells were plated onto 35-mm plates coated with ®bronectin (5 mg/cm 2 ). In some experiments, cells were ®rst treated with 10 Gy ionizing radiation using a Gammacell 1000 (Atomic Energy of Canada). Twenty hours after plating, cells were observed under phase-contrast microscopy using a Olympus inverted system microscope IX70 to look for changes in morphology. Similarly, in some experiments, cells were examined by video microscopy using a Olympus inverted system microscope IX70, Omega temperature control device for controlling the temperature and CO 2 , Optronics Engineering DEI-750 3CCD digital video camera, and Sony SVT-S3100 time-lapse S-VHS video recorder. For imaging presentation, video images were captured and printed with the Sony Color Video Printer UP-5600MD.
